# Yi-Long Wu

Source: https://onco.cc/people/wu-yi-long/  
OnCo record `wu-yi-long` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.

## Summary

Yi-Long Wu is Professor at the Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, and a leader of the Chinese Thoracic Oncology Group. He is among the most cited lung cancer trialists in the world, co-principal investigator of ADAURA, which tested adjuvant osimertinib in resected EGFR-mutated non-small-cell lung cancer, and a leader of IPASS and ADJUVANT-CTONG, the trials that made EGFR-targeted pills standard before and after surgery. His publications include the ADAURA report on osimertinib in resected EGFR-mutated lung cancer. His interests are EGFR-mutant disease, adjuvant targeted therapy and clinical trials.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
- Specialisms: Lung cancer; EGFR-mutant NSCLC; Adjuvant targeted therapy; Clinical trials

## Sources

- Guangdong Lung Cancer Institute: https://www.gdghospital.org.cn
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Wu%20YL%5BAuthor%5D%20Guangdong%20Lung%20Cancer%20Institute%20osimertinib

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [Chinese Thoracic Oncology Group](https://onco.cc/companies/ctong/)
- institutions: [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [Guangdong Provincial People's Hospital](https://onco.cc/institutions/guangdong-provincial-peoples-hospital/), [International Association for the Study of Lung Cancer](https://onco.cc/institutions/iaslc/)
- trials: [ADAURA](https://onco.cc/trials/adaura/), [ARCHER 1050](https://onco.cc/trials/nct01774721/)
- key papers: [ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer](https://onco.cc/key-papers/paper-adaura-8-year-os-jto-2026/), [ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-adaura-nejm-2020/), [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://onco.cc/key-papers/paper-archer-1050-lancet-oncol-2017/), [Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations](https://onco.cc/key-papers/paper-archer-1050-os-jco-2018/)

---
JSON: https://onco.cc/api/v1/entities/wu-yi-long.json